Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care, urology and surgery, is committed to connecting clinicians with technology in a way that improves clinical practice and advances patient outcomes. Teleflex will showcase its Arrow® EZ-IO® Intraosseous Vascular Access System and other products for rescue airway, atomization and intubation needs at the first European Emergency Medical Service Congress (“EMS 2016”) to be held in Copenhagen, Denmark, on May 30-June 1, 2016.

Achieving better treatment for the patient is the goal of this event, which will highlight the latest knowledge on best practices and the newest equipment in the area of emergency medical services and pre-hospital care.

This is a perfect setting for Teleflex to focus on its Arrow® EZ-IO® Intraosseous Vascular Access System.

The Arrow® EZ-IO® Intraosseous Vascular Access System from Teleflex is an innovative and complete solution for rapid vascular access – whether the emergency responder is facing difficult vascular access challenges or the need for fast intraosseous access for critical situations and life-threatening emergencies. This system is designed to provide the medical professional vascular access to the central circulation system within seconds1, delivering medications, intravenous fluids and blood products to adult and pediatric patients alike.

The Teleflex Clinical & Medical Affairs team will be at the booth to conduct resuscitation scenarios on high fidelity simulation models. The team of highly experienced clinicians will demonstrate the latest evidence based interventions related to intraosseous needle placement. These interactive sessions will help educate clinicians from around Europe, improving patient outcomes through advancing clinical practice.

Teleflex will also feature the LMA® Supreme™ Airway and the LMA® MAD Nasal™ Intranasal Mucosal Atomization Device.

The LMA® Supreme™ Airway is the market leading second generation subglottic airway. The gastric drain tube channels secretions away from the airway in compliance with NAP4 guidelines. Effective first and second seal technology truly separates the digestive tract from the airway making this the first choice subglottic airway for emergency use.

When IV drug delivery is less than ideal, the LMA® MAD Nasal™ Device2 from Teleflex can come to the rescue, delivering safe, painless and rapidly effective treatment. No needle. No trauma. No risk of needle stick injury.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, EZ-IO, Hudson RCI, LMA, LMA Supreme, MAD Nasal, Pilling, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2016 Teleflex Incorporated. All rights reserved.

References:

1. Von Hoff DD , Kuhn JG, Burris HA, Miller LJ. Does intraosseous equal intravenous? A pharmacokinetic study. Amer J Emerg Med 2008;26:31-8

2. For use with drugs approved for intranasal delivery

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836orMartina Teichmann-ZindlerDirector Marketing Communications International+49 (0)7151-406-538martina.teichmann@teleflex.com

Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Teleflex Charts.
Teleflex (NYSE:TFX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Teleflex Charts.